Tradestie Institutional Equity Comparison Engine

ERAS vs ANL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ERAS Overall Edge

ERAS Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Erasca, Inc. Common Stock (ERAS) driven by superior Growth & Margin, Options & Structure while ANL counters with relative strength in Momentum & Technical. Fundamentally, ERAS trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ANL at N/M Forward P/E and -123.5% operating margin (+178.1% YoY). In options structure, ERAS sits in BREAKDOWN (13th %ile IV; Dealer Gamma Walls on Pro) against ANL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ERAS N/M vs ANL N/M Fwd P/E
Growth & Margin Winner ERAS
Op Margin 0.0% vs -123.5% ยท YoY +0.0% vs +178.1%
Momentum & Technical Winner ANL
1Y +488.4% vs +560.3% ยท 52W Pos 57% vs 56%
Options & Structure Winner ERAS
BREAKDOWN (13th %ile IV) vs UNCLASSIFIED (N/A IV)
ERAS NASDAQ
Erasca, Inc. Common Stock
Pharmaceutical Preparations
$14.95
-4.57% 1D
Market Cap $5.5B
1M Return +11.61%
1Y Return +488.39%
Forward P/E N/M
Unified AI Score
37.5 / 100 SELL
Tech 20.0 Fund 47.0 Flow 70.0 Mom 64.0
ANL US Equity
ANL
Institutional Equity
$9.97
-6.03% 1D
Market Cap $677.5M
1M Return -9.61%
1Y Return +560.26%
Forward P/E N/M
Unified AI Score
48.3 / 100 HOLD
Tech 48.0 Fund 52.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ERAS +488.39% ANL +560.26% Spread: +71.87 pp (ANL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ERAS TTM Op. Margin: 0.0% ANL TTM Op. Margin: -123.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ERAS vs ANL. Trailing 12-month operating profitability (ERAS 0.0% vs ANL -123.5%) and valuation multiples (ERAS N/M vs ANL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ERAS (4) vs ANL (4)
Institutional Metric ERAS ANL Criterion Row Winner
Market Capitalization Scale $5.5B $677.5M Larger Scale ERAS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +178.1% Higher Growth ANL
Operating Margin (TTM) Profitability 0.0% -123.5% Higher Margin ERAS
Net Profit Margin Profitability 0.0% -124.8% Higher Margin ERAS
Return on Equity (ROE) Capital Efficiency -48.7% -20.2% Higher ROE ANL
52-Week Range Position Momentum 57% ($2โ€“$24) 56% ($1โ€“$17) Stronger Trend ERAS
Beta / 30D Volatility Risk Regime 2.31ฮฒ ยท 81% Vol 2.61ฮฒ ยท 79% Vol Lower Realized Risk ANL
Unified Institutional Score Composite Signal 37.5 / 100 (SELL) 48.3 / 100 (HOLD) Higher Composite ANL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ERAS vs ANL Buy Guide
ERAS BREAKDOWN
87d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ERAS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ANL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ANL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ERAS nor ANL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.